| 臺大學術典藏 |
2021-05-07T06:02:39Z |
Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families
|
Yu K.J.;Hsu W.-L.;Pfeiffer R.M.;Chun-Ju Chiang ;Wang C.-P.;Lou P.-J.;Cheng Y.-J.;Gravitt P.;Diehl S.R.;Goldstein A.M.;Chen C.-J.;Hildesheim A.; Yu K.J.; Hsu W.-L.; Pfeiffer R.M.; CHUN-JU CHIANG; Wang C.-P.; Lou P.-J.; Cheng Y.-J.; Gravitt P.; Diehl S.R.; Goldstein A.M.; Chen C.-J.; Hildesheim A. |
| 臺大學術典藏 |
2021-05-07T06:02:39Z |
Familial tendency and risk of nasopharyngeal carcinoma in Taiwan: Effects of covariates on risk
|
Hsu W.-L.;Yu K.J.;Chien Y.-C.;Chun-Ju Chiang ;Cheng Y.-J.;Chen J.-Y.;Liu M.-Y.;Chou S.-P.;You S.-L.;Hsu M.-M.;Lou P.-J.;Wang C.-P.;Hong J.-H.;Leu Y.-S.;Tsai M.-H.;Su M.-C.;Tsai S.-T.;Chao W.-Y.;Ger L.-P.;Chen P.-R.;Yang C.-S.;Hildesheim A.;Diehl S.R.;Chen C.-J.; Hsu W.-L.; Yu K.J.; Chien Y.-C.; CHUN-JU CHIANG; Cheng Y.-J.; Chen J.-Y.; Liu M.-Y.; Chou S.-P.; You S.-L.; Hsu M.-M.; Lou P.-J.; Wang C.-P.; Hong J.-H.; Leu Y.-S.; Tsai M.-H.; Su M.-C.; Tsai S.-T.; Chao W.-Y.; Ger L.-P.; Chen P.-R.; Yang C.-S.; Hildesheim A.; Diehl S.R.; Chen C.-J. |
| 臺大學術典藏 |
2021-05-07T06:02:34Z |
Lifetime risk of distinct upper aerodigestive tract cancers and consumption of alcohol, betel and cigarette
|
Hsu W.-L.;Chien Y.-C.;Chun-Ju Chiang;Yang H.-I.;Lou P.-J.;Wang C.-P.;Yu K.J.;You S.-L.;Wang L.-Y.;Chen S.-Y.;Yang C.-S.;Chen C.-J.; Hsu W.-L.; Chien Y.-C.; CHUN-JU CHIANG; Yang H.-I.; Lou P.-J.; Wang C.-P.; Yu K.J.; You S.-L.; Wang L.-Y.; Chen S.-Y.; Yang C.-S.; Chen C.-J. |
| 臺大學術典藏 |
2021-03-03T03:00:57Z |
Corrigendum to "Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials", [Urol Sci, (2015), 41-48], doi:10.1016/j.urols.2014.12.010
|
Kuo H.-C.; HO-HSIUNG LIN; Yu H.-J.; Cheng C.-L.; Hung M.-J.; Lin A.T.L.; Chang C.-H.; Chuang Y.-C.; Cha T.-L.; Chen G.-D.; Chen C.-S.; Wu M.-P.; Wu T.-L.; Yu K.-J.; Huang S.-T.; The Taiwan Mirabegron Study Team |
| 臺大學術典藏 |
2021-02-02T02:20:50Z |
Evaluation of rare and common variants from suspected familial or sporadic nasopharyngeal carcinoma (NPC) susceptibility genes in sporadic NPC
|
Liu Z.; Goldstein A.M.; Hsu W.-L.; Yu K.J.; Chien Y.-C.; Ko J.-Y.; Jian J.J.-M.; Tsou Y.-A.; Leu Y.-S.; Liao L.-J.; Chang Y.-L.; Wang C.-P.; Wu J.-S.; Hua C.-H.; Lee J.-C.; Yang T.-L.; Hsiao C.K.; MING-SHIANG WU; Tsai M.-H.; Huang K.-K.; Yu K.; Jones K.; Zhu B.; Yeager M.; Yu G.; Lou P.-J.; Chen C.-J.; Hildesheim A.; for the GEV-NPC group |
| 臺大學術典藏 |
2021-02-02T02:20:41Z |
Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis
|
Hsu W.-L.; Chien Y.-C.; Huang Y.-T.; Yu K.J.; Ko J.-Y.; Lin C.-Y.; Tsou Y.-A.; Leu Y.-S.; Liao L.-J.; Chang Y.-L.; Su J.-Y.; Liu Z.; Wang C.-P.; Terng S.-D.; Hua C.-H.; Lee J.-C.; Yang T.-L.; Kate Hsiao C.-H.; MING-SHIANG WU; Tsai M.-H.; Liu M.-J.; Lou P.-J.; Hildesheim A.; Chen C.-J.; the GEV-NPC Study Group |
| 臺大學術典藏 |
2021-02-02T00:43:02Z |
Corrigendum to "Results of a randomized, double-blind, placebo-controlled study of mirabegron in a Taiwanese population with overactive bladder and comparison with other clinical trials", [Urol Sci, (2015), 41-48], doi:10.1016/j.urols.2014.12.010
|
Kuo H.-C.; Lin H.-H.; HONG-JENG YU; Cheng C.-L.; Hung M.-J.; Lin A.T.L.; Chang C.-H.; Chuang Y.-C.; Cha T.-L.; Chen G.-D.; Chen C.-S.; Wu M.-P.; Wu T.-L.; Yu K.-J.; Huang S.-T.; The Taiwan Mirabegron Study Team |
| 臺大學術典藏 |
2021-01-28T08:27:29Z |
Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing
|
LIN P.-H.; HUANG C.-Y.; YU K.-J.; KAN H.-C.; LIU C.-Y.; CHUANG C.-K.; YU-CHUAN LU; CHANG Y.-H.; SHAO I.H.; PANG S.-T. |
| 臺大學術典藏 |
2020-11-03T15:39:36Z |
Familial tendency and risk of nasopharyngeal carcinoma in Taiwan: Effects of covariates on risk
|
Chen P.-R; Yang C.-S; Hildesheim A; Diehl S.R; Chen C.-J.; Hsu M.-M; Lou P.-J; CHENG-PING WANG; Hong J.-H; Leu Y.-S; Tsai M.-H; Su M.-C; Tsai S.-T; Chao W.-Y; Ger L.-P; Chou S.-P; You S.-L; Chen J.-Y; Liu M.-Y; Cheng Y.-J; Chiang C.-J; Chien Y.-C; Yu K.J; Hsu W.-L |
| 臺大學術典藏 |
2020-11-03T15:39:35Z |
Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families
|
Yu K.J; Hsu W.-L; Pfeiffer R.M; Chiang C.-J; CHENG-PING WANG; Lou P.-J; Cheng Y.-J; Gravitt P; Diehl S.R; Goldstein A.M; Chen C.-J; Hildesheim A. |
